Amlodipine and Telmisartan combination offers swift, effective BP control along with end-organ protection in hypertensive patients with diabetes: Study
Hypertension and diabetes - the deadly duo!
Hypertension or high blood pressure (BP), the leading cause of mortality, affects nearly 1.39 billion people worldwide. India contributes 234 million adults to this figure. (1,2) Moreover, hypertension is also a major risk factor for microvascular complications, atherosclerotic cardiovascular disease (ASCVD) and heart failure. In India, hypertension occurs in nearly twice the number of people with diabetes than without diabetes. On the other hand, 1 out of every 3 individuals with diabetes develops hypertension in subsequent years.(4) The coexistence of hypertension with diabetes enhances the risk of ASCVD in these individuals, increasing their associated morbidity and mortality rates. (3) This is reflected in healthcare costs wherein Indian patients with both diabetes and hypertension spend 1.4 times more than patients with hypertension alone.(4)
Switching to a combination for the treatment of hypertension in patients with diabetes
• Single-pill combination (SPC) of two agents has been found to decrease CV events in patients with diabetes & hypertension and can also facilitate a swift and sustained reduction in BP levels
• Switching to the SPC therapy of Amlodipine and Telmisartan led to a substantially greater decrease in BP levels, increase in BP response and BP goal achievement rates compared to Amlodipine monotherapy